Angeion Corporation (NASDAQ: ANGN) announced that it will be showcasing its newly enhanced Ultima™ CardiO 2 complete metabolic stress testing system and BreezeSuite™ 7 software platform at the 2010 American Thoracic Society (ATS) International Conference. ATS 2010 is the world’s premier educational program for clinicians and researchers in pulmonary, critical care and sleep medicine. The event is taking place at the Morial Convention Center, New Orleans, May 14 to 19, 2010.
Angeion will be exhibiting at booth #1409. The Ultima CardiO 2, part of the company’s MedGraphics product line, is produced in partnership with Mortara Instrument, Inc. The system is driven by MedGraphics’ BreezeSuite 7 platform that combines gas exchange and pulmonary function testing into one, easy-to-use software package. With electrocardiography (ECG) and true breath-by-breath analysis, the Ultima CardiO 2 enables clinicians to quickly and efficiently measure key pulmonary, cardiopulmonary and nutritional functions.
“ATS 2010 is a great opportunity to encourage clinicians and researchers from around the world to ‘Think Outside the Box’ and experience the advantages of Angeion’s diagnostic products, particularly our true breath-by-breath capabilities,” said Rodney A. Young, President and Chief Executive Officer. “This event is one of the largest health care conferences in the world, and we look forward to showcasing our products to a global audience.”
In addition to Ultima CardiO 2 and BreezeSuite 7 Platform, Angeion will display its broad line of MedGraphics products including the CCM Express®, CPFS/D™ and Platinum Elite™.More than 14,000 physicians, clinicians and technicians from 90 countries will attend ATS 2010. The conference program offers information on the latest and most significant developments in clinical practice, research, health advocacy and education. About Angeion Corporation Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics ( www.medgraphics.com) and New Leaf ( www.newleaffitness.com) brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications in health care as well as health and fitness. The Company’s products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians’ offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit www.angeion.com. The discussion above contains forward-looking statements about Angeion’s future financial results and business prospects that by their nature involve substantial risks and uncertainties. You can identify these statements by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “project,” “intend,” “plan,” “will,” “target,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Our actual results may differ materially depending on a variety of factors including: (1) national and worldwide economic and capital market conditions; (2) continuing cost-containment efforts in our hospital, clinics, and office market; (3) our ability to successfully operate our business, including our ability to develop, improve, and update our cardiorespiratory diagnostic products and successfully sell these products under the MedGraphics and New Leaf brand names into existing and new markets; (4) our ability to maintain our cost structure at a level that is appropriate to our near to mid-term revenue expectations and that will enable us to increase revenues and profitability as opportunities develop; (5) our ability to achieve constant margins for our products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers; (6) our ability to effectively manufacture and ship products in required quantities to meet customer demands; (7) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (8) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products; (9) our ability to defend our intellectual property; (10) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures; and (11) our dependence on third-party vendors. Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the above discussion is qualified in its entirety by, the other risk factors that are described from time to time in the Company’s Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2009.